Pharmacokinetics: Metabolism and Excretion — MCQs
The cytochrome involved in monooxygenase-mediated detoxification of drugs is:
A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?
A substance has a clearance similar to inulin clearance. How is this substance primarily excreted in urine?
What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
A patient on warfarin has a high INR. Which drug likely caused this?
Bile salts undergo conjugation for enhanced solubility:
Which statement best describes first-order kinetics in pharmacokinetics?
Which beta blocker is considered safer for use in patients with hepatic disease?
Which of the following drugs is metabolized by CYP2D6?
Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?
Pharmacokinetics: Metabolism and Excretion Indian Medical PG Practice Questions and MCQs
Question 1: The cytochrome involved in monooxygenase-mediated detoxification of drugs is:
- A. Cyt P 450 (Correct Answer)
- B. Cytochrome b5
- C. Cytochrome c
- D. Cytochrome oxidase
Explanation: ***Cyt P 450*** - **Cytochrome P450 (CYP450)** enzymes are a superfamily of heme-containing monooxygenases primarily responsible for the **metabolism of xenobiotics**, including the detoxification of drugs. - They catalyze oxidation reactions, introducing a hydroxyl group to substrates, which typically increases their **hydrophilicity** and facilitates excretion. *Cytochrome c* - **Cytochrome c** is a component of the **electron transport chain** in mitochondria, primarily involved in cellular respiration and energy production. - It acts as an **electron carrier** between Complex III and Complex IV, not directly in drug detoxification. *Cytochrome b5* - **Cytochrome b5** participates in various metabolic reactions, including **fatty acid desaturation** and cholesterol biosynthesis, and can sometimes assist CYP450 enzymes. - However, it does not function as a primary monooxygenase for drug detoxification itself. *Cytochrome oxidase* - **Cytochrome oxidase** (Complex IV) is the terminal enzyme in the **electron transport chain**, responsible for the reduction of oxygen to water. - Its main role is in cellular respiration, and it is not directly involved in drug monooxygenation or detoxification.
Question 2: A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?
- A. 120 hours
- B. 140-180 hours
- C. 1 half-life (40 hours)
- D. 80 hours (Correct Answer)
Explanation: ***80 hours (2 half-lives)***- Current digoxin level is **4 ng/mL**, which is **twice the upper therapeutic limit** (2 ng/mL), causing toxicity with nausea and vomiting [1]- After **1 half-life (40 hours)**: concentration reduces to 2 ng/mL (upper therapeutic limit) [2]- After **2 half-lives (80 hours)**: concentration reduces to 1 ng/mL (mid-therapeutic range) [2]- **Clinical rationale**: While 2 ng/mL is technically within range, waiting for 2 half-lives ensures the level is comfortably in the **middle of the therapeutic window** (1 ng/mL), providing a **safer margin** before resuming treatment in a patient who just experienced toxicity- This conservative approach minimizes risk of recurrent toxicity, especially important given the patient's recent symptoms at 4 ng/mL*1 half-life (40 hours)*- After 1 half-life, digoxin level would be 2 ng/mL, which is at the **upper limit** of the therapeutic range- While technically within the therapeutic range, this leaves **minimal safety margin** in a patient who just experienced toxicity- Starting treatment immediately at this level carries higher risk of recurrent side effects*120 hours (3 half-lives)*- After 3 half-lives, the concentration would be **0.5 ng/mL**, which is **below the therapeutic range** (1-2 ng/mL)- This is overly conservative and would **unnecessarily delay** resumption of essential cardiac medication- Could lead to inadequate control of the underlying condition (heart failure or atrial fibrillation)*140-180 hours (3.5-4.5 half-lives)*- This would reduce digoxin to **0.25-0.35 ng/mL**, well below therapeutic levels- This **excessive delay** is not clinically justified and could worsen the patient's cardiac condition- No standard protocol recommends waiting this long before resuming digoxin therapy
Question 3: A substance has a clearance similar to inulin clearance. How is this substance primarily excreted in urine?
- A. Tubular Secretion
- B. Glomerular filtration (Correct Answer)
- C. Vascular leakage
- D. Both tubular secretion and glomerular filtration
Explanation: ***Glomerular filtration*** - **Inulin** is a gold standard for measuring **glomerular filtration rate** (GFR) because it is freely filtered by the glomeruli and is neither reabsorbed nor secreted by the renal tubules. - Therefore, a substance with clearance similar to inulin is primarily excreted via **glomerular filtration**. *Tubular Secretion* - If a substance were primarily excreted by tubular secretion, its clearance would be **higher than the GFR**, as secretion adds more of the substance to the urine than filtration alone. - This mechanism is characteristic of substances like **para-aminohippurate (PAH)**, which is used to measure renal plasma flow. *Vascular leakage* - **Vascular leakage** is not a normal mechanism of substance excretion in the urine. - It refers to the abnormal passage of fluid and macromolecules from blood vessels into tissues, often seen in conditions like inflammation or sepsis, and does not directly contribute to renal clearance. *Both tubular secretion and glomerular filtration* - If a substance were excreted by both **tubular secretion and glomerular filtration**, its clearance would also be **higher than the GFR**, similar to substances that undergo significant tubular secretion. - The fact that its clearance is *similar* to inulin specifically points to filtration as the predominant and almost exclusive mechanism.
Question 4: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
- A. First pass kinetics
- B. First order kinetics
- C. Zero order kinetics (Correct Answer)
- D. Second order kinetics
Explanation: ***Zero order kinetics*** - This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time. - Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses. *First pass kinetics* - This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration. - While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses. *First order kinetics* - In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration. - Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated. *Second order kinetics* - This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants. - It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.
Question 5: A patient on warfarin has a high INR. Which drug likely caused this?
- A. Amiodarone (Correct Answer)
- B. Phenytoin
- C. Carbamazepine
- D. Rifampicin
Explanation: ***Amiodarone*** - Amiodarone is a well-known inhibitor of **CYP2C9**, the primary enzyme responsible for the metabolism of **S-warfarin**, the more potent enantiomer of warfarin. - Inhibition of warfarin metabolism leads to increased warfarin levels, thereby enhancing its anticoagulant effect and causing a **higher INR**. *Phenytoin* - Phenytoin is an **enzyme inducer**, primarily of **CYP2C9** and **CYP3A4**. - Its interaction with warfarin typically leads to **decreased warfarin levels** and a **lower INR**, reducing the anticoagulant effect. *Carbamazepine* - Carbamazepine is a potent **enzyme inducer**, particularly of **CYP3A4** and **CYP2C9**. - Like phenytoin, it generally leads to **increased warfarin metabolism** and a **reduced INR**, thereby decreasing its anticoagulant efficacy. *Rifampicin* - Rifampicin is a strong **inducer of hepatic cytochrome P450 enzymes**, especially **CYP3A4** and **CYP2C9**. - Its co-administration with warfarin significantly **increases warfarin metabolism**, resulting in **lower warfarin concentrations** and a **decreased INR**.
Question 6: Bile salts undergo conjugation for enhanced solubility:
- A. After conjugation with derived proteins
- B. After conjugation with lysine
- C. After conjugation with taurine and glycine (Correct Answer)
- D. After conjugation with betaglucuronic acid
Explanation: ***After conjugation with taurine and glycine*** - This statement accurately describes the most common conjugation pathway for bile acids, increasing their **amphipathic properties** and solubility. - Conjugation with these amino acids forms **bile salts** (e.g., glycocholate, taurocholate), which are essential for **micelle formation** and fat digestion. - This is the primary mechanism by which bile acids become bile salts with enhanced solubility. *After conjugation with betaglucuronic acid* - While bile acids do undergo conjugation for increased solubility, they are primarily conjugated with glycine or taurine, not beta-glucuronic acid. - Conjugation with beta-glucuronic acid is a common detoxification pathway for many xenobiotics and bilirubin, but not the primary method for bile acids. *After conjugation with derived proteins* - Bile salts are primarily steroid derivatives and are not conjugated with derived proteins. - The purpose of conjugation is to increase hydrophilicity, which proteins would not achieve in this context. *After conjugation with lysine* - Lysine is an amino acid but is not involved in the conjugation of bile acids. - Bile acid conjugation specifically uses the amino acids glycine and taurine.
Question 7: Which statement best describes first-order kinetics in pharmacokinetics?
- A. Absorption of the drug is independent of the serum concentration
- B. Elimination of the drug is proportional to the serum concentration (Correct Answer)
- C. Absorption of the drug is proportional to the serum concentration
- D. Elimination of the drug is independent of the serum concentration
Explanation: ***Elimination of the drug is proportional to the serum concentration*** - In **first-order kinetics**, a **constant fraction** (or percentage) of the drug is eliminated per unit of time. - This means that as the **serum drug concentration** increases, the absolute amount of drug eliminated per unit time also increases proportionally. *Absorption of the drug is independent of the serum concentration* - Drug absorption is generally driven by factors like **concentration gradient**, surface area, and blood flow, and while it can be influenced by drug concentration, this statement does not define first-order kinetics of *elimination*. - This statement is not the primary characteristic distinguishing first-order from zero-order kinetics regarding drug disposition. *Elimination of the drug is independent of the serum concentration.* - This describes **zero-order kinetics**, where a **constant amount** of drug is eliminated per unit of time, regardless of the serum concentration. - In zero-order kinetics, the elimination rate becomes saturated, so the elimination process cannot keep up with higher drug concentrations. *Absorption of the drug is proportional to the serum concentration* - While drug absorption can be proportional to the concentration (especially through passive diffusion), first-order kinetics specifically refers to the **elimination phase** of pharmacokinetics. - The rate of absorption can be a complex process and is not the defining characteristic for distinguishing first-order from zero-order *elimination*.
Question 8: Which beta blocker is considered safer for use in patients with hepatic disease?
- A. Esmolol (Correct Answer)
- B. Betaxolol
- C. Bisoprolol
- D. Carvedilol
Explanation: **Correct: Esmolol** - **Esmolol** is primarily metabolized by **plasma esterases** (red blood cell esterases), not the liver, making it the safest beta-blocker for patients with **hepatic impairment**. - Its **ultra-short half-life** (approximately 9 minutes) and rapid extrahepatic metabolism minimize drug accumulation and adverse effects in liver disease. - Commonly used in acute settings (ICU, perioperative) where rapid titration is needed. *Incorrect: Betaxolol* - **Betaxolol** is primarily metabolized by the **liver**, and its half-life can be significantly prolonged in patients with hepatic dysfunction. - This increased half-life can lead to **drug accumulation** and an elevated risk of adverse effects such as bradycardia and hypotension. *Incorrect: Bisoprolol* - **Bisoprolol** is eliminated by both **hepatic metabolism** (50%) and **renal excretion** (50%); however, significant liver impairment can still affect its clearance. - While it has a dual elimination pathway providing some safety margin, dose adjustments are often required in severe hepatic dysfunction. *Incorrect: Carvedilol* - **Carvedilol** is extensively metabolized by the **liver**, primarily through CYP2D6 and CYP2C9, leading to significantly altered pharmacokinetics in hepatic disease. - It should be **used with caution in hepatic impairment** due to substantial increase in bioavailability (up to 4-fold) and risk of adverse events including severe hypotension.
Question 9: Which of the following drugs is metabolized by CYP2D6?
- A. Propranolol (Correct Answer)
- B. Warfarin
- C. Statins
- D. Amiodarone
Explanation: ***Correct Answer: Propranolol*** - **Propranolol** is a non-selective beta-blocker that undergoes extensive **first-pass metabolism**, primarily via the **CYP2D6** and CYP1A2 enzymes. - Genetic variations in **CYP2D6** can significantly affect propranolol's metabolism, leading to altered drug levels and therapeutic responses. *Incorrect: Warfarin* - **Warfarin** is predominantly metabolized by **CYP2C9**, with minor contributions from other CYP enzymes. - Genetic polymorphisms in **CYP2C9** are a major factor in determining individual warfarin dose requirements. *Incorrect: Statins* - Most **statins** (e.g., simvastatin, lovastatin, atorvastatin) are primarily metabolized by **CYP3A4**. - **Fluvastatin** is an exception, being mainly metabolized by CYP2C9, while **rosuvastatin** is largely unmetabolized. *Incorrect: Amiodarone* - **Amiodarone** is primarily metabolized by **CYP3A4** and to a lesser extent by CYP2C8. - Due to its **long half-life** and extensive metabolism, amiodarone has numerous drug interactions, often involving CYP3A4 inhibition.
Question 10: Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?
- A. Brand A is bioequivalent to brand B (Correct Answer)
- B. Brand A is not bioequivalent to brand B
- C. Brand A has higher volume of distribution than brand B
- D. Brand B has higher volume of distribution than brand A
Explanation: ***Brand A is bioequivalent to brand B*** - **Bioequivalence** is generally established if the **90% confidence interval** for the ratio of the **AUC** (and Cmax) of the test product (Brand B) to the reference product (Brand A) falls within **80-125%**. - Here, the ratio of AUC (Brand B / Brand A) is 115/124 ≈ 0.927 or 92.7%. This value falls well within the accepted range of 80-125%, indicating bioequivalence. *Brand A is not bioequivalent to brand B* - This statement is incorrect because the AUC ratio (115/124 ≈ 0.927) is within the **standard bioequivalence range of 80-125%**, indicating that the two brands are indeed bioequivalent. - While there are differences in Cmax and Tmax for the two brands as shown in the graph, the provided AUC values suggest bioequivalence for the overall drug exposure. *Brand A has higher volume of distribution than brand B* - The provided **AUC values** (Area Under the Curve) primarily reflect the **extent of drug exposure** and are not directly indicative of the **volume of distribution (Vd)**. - Vd is a pharmacokinetic parameter that relates the total amount of drug in the body to the concentration of the drug in plasma, and it cannot be directly inferred from AUC values alone without additional information like dose and clearance. *Brand B has higher volume of distribution than brand A* - Similar to the previous option, AUC values alone are insufficient to determine the relative **volume of distribution** between the two brands. - Changes in Vd would affect the peak concentration (Cmax) and the elimination half-life, but a definitive conclusion requires more comprehensive pharmacokinetic analysis.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free